Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116272 · ClinicalTrials.gov registry record
Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 830
- Enrollment target
NCT00116272 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 830 participants.
The verdict
NCT00116272 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 830 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of etanercept when used in the first trimester of pregnancy with respect to major structural birth defects of newborns. This is an observational study only - no investigational product is used.
Interventions
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2005-04 |
| Est. Completion | 2014-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116272
The ClinicalTrials.gov registry entry for NCT00116272 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT00116272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116272 about?
NCT00116272 is a clinical study titled "Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project". The purpose of the study is to evaluate the effect of etanercept when used in the first trimester of pregnancy with respect to major structural birth defects of newborns. This is an observational study only - no investigational product is used.
What is the current status of trial NCT00116272?
This trial is currently completed. The enrollment target is 830 participants. The study started on 2005-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00116272?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00116272?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.